Welcome to the Future of Engineered CTx, Harnessing RNA for Safety, Versatility, and Manufacturability
RNA technologies have taken the world by storm over the pandemic and now the potential to of RNA engineering to enhance cell therapy is finally being realized.
The therapeutic potential of RNA CTx is huge, but challenges remain in cell-specific delivery, improving durability of responses, demonstrating safety and elucidating regulatory considerations to deliver for patients.
The inaugural RNA Cell Therapy Summit is the first of its kind to unite 80+ industry and academic pioneers from both the RNA and cell therapy field to bridge-the-gap between transient RNA engineering and cell therapy development.
Join industry trailblazers at Cartesian, Sanofi, Intellia, Editas, Capstan and more to future-proof your pipeline with the pinnacle of cell engineering to develop the next-generation of safer, more functional and scalable CTx through the clinic.
Your 2022 Expert Speaker Faculty:
Senior Vice President, Cell Therapies
Chief Medical Officer
Chief Scientific Officer
Qiming Venture Partners
Senior Research Director, Immunology
Tidal (a Sanofi Company)
Research Assistant Professor of Medicine
Perelman School of Medicine, University of Pennsylvania
Proud to Partner With:
What attendees from other RNA/Cell Therapy meetings have to say:
“An outstanding conference to understand where we are in the field, the challenges and opportunities.” Jagesh Shah, Vice President, Gene Therapy Technologies, Sana Biotechnology
“Inspiring to meet like-minded scientists discussing the trials, concerns and successes”
Brett Staahl, Co-Founder & Vice President – Platform, Scribe Therapeutics
“I connected with colleagues that I didn't know before and learned a lot about the current state of mRNA development/manufacturing and the existing pain points in the industry.” Marc Sauer, Chief Science Officer, BioVectra